相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models
Mingqiang Li et al.
BIOMATERIALS (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
Simone Meidhof et al.
EMBO MOLECULAR MEDICINE (2015)
HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT
Ji Heon Noh et al.
CANCER RESEARCH (2014)
Antitumor Effects in Hepatocarcinoma of lsoform-Selective Inhibition of HDAC2
Yun-Han Lee et al.
CANCER RESEARCH (2014)
Histone deacetylase inhibitors and cell death
Jing Zhang et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells
Tsai-Hsien Hung et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
Long Noncoding RNA MRUL Promotes ABCB1 Expression in Multidrug-Resistant Gastric Cancer Cell Sublines
Ying Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Current status of screening for colorectal cancer
K. Garborg et al.
ANNALS OF ONCOLOGY (2013)
Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1
Wing-Kee Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Long-term results and prognostic factors after resection of hepatic and pulmonary metastases of colorectal cancer
Silke Schuele et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2013)
Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation
Ruizan Shi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1
Jonathan T. Sims et al.
PLOS ONE (2013)
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemoresistance of invasive micropapillary carcinoma of the breast
Sophie Doublier et al.
BMC CANCER (2012)
LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
Prue A. Cowin et al.
CANCER RESEARCH (2012)
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins
Kwang Hwa Jung et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Signal Transduction Pathways and Transcriptional Mechanisms of ABCB1/Pgp-mediated Multiple Drug Resistance in Human Cancer Cells
H. Sui et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Histone deacetylases and cancer
Bruna Barneda-Zahonero et al.
MOLECULAR ONCOLOGY (2012)
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells
Valentina Colombo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Pharmacogenetics of Membrane Transporters: An Update on Current Approaches
Tristan M. Sissung et al.
MOLECULAR BIOTECHNOLOGY (2010)
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma
Hassan Ashktorab et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Decreased ABCB1 mRNA expression induced by atorvastatin results from enhanced mRNA degradation in HepG2 cells
Alice Cristina Rodrigues et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
P. Fritsche et al.
GUT (2009)
The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair
P. Maiso et al.
LEUKEMIA (2009)
HDAC2 deficiency sensitizes colon cancer cells to TNFα-induced apoptosis through inhibition of NF-κB activity
Pawan Kaler et al.
EXPERIMENTAL CELL RESEARCH (2008)
Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells
Rosaline C-Y. Hui et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice
Stephan Zimmermann et al.
CANCER RESEARCH (2007)
Histone deacetylase inhibitor trichostatin A potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression
Lina Pan et al.
CANCER (2007)
Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression
Ketki M. Hatle et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas
Cameron C. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells
Maria G. Catalano et al.
JOURNAL OF ENDOCRINOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
P Zhu et al.
CANCER CELL (2004)
The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair
J Hayakawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation
LD Cripe et al.
LEUKEMIA (2002)
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling
MT Kuo et al.
ONCOGENE (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
分享论文
